Michael J Li1, Marisa S Briones2, Keith G Heinzerling2, Mariah M Kalmin2, Steven J Shoptaw2. 1. Center for Behavioral and Addiction Medicine, Department of Family Medicine, University of California, Los Angeles, United States; Division of Infectious Diseases, University of California, Los Angeles, United States. Electronic address: mjli@mednet.ucla.edu. 2. Center for Behavioral and Addiction Medicine, Department of Family Medicine, University of California, Los Angeles, United States.
Abstract
BACKGROUND: Preclinical studies suggest that the non-selective phosphodiesterase inhibitor, Ibudilast (IBUD) may contribute to the treatment of methamphetamine (METH) use disorder through the attenuation of METH-induced inflammatory markers such as adhesion molecules, sICAM-1 and sVCAM-1, and cytokines, IL-6 and TNF-α. OBJECTIVE: The present study aimed to test whether treatment with IBUD can attenuate peripheral markers of inflammation during a METH challenge in an inpatient clinical trial of 11 patients. METHODS: This trial followed a randomized, within-subjects crossover design where participants received a METH challenge, during which five participants were treated with placebo then with IBUD, while the remaining six participants were treated with IBUD prior to placebo. Mixed effects regression modeled changes in peripheral markers of inflammation-sICAM-1, sVCAM-1, TNF-α, IL-6, MIF, and cathepsin D-by treatment condition, with measurements at baseline, 60 min post-METH infusion, and 360 min post-METH infusion. RESULTS: While on placebo, sICAM-1, sVCAM-1, and cathepsin D significantly increased by 60 min post-METH infusion, while IL-6 significantly increased 360 min post-METH infusion. Treatment with IBUD significantly reduced METH-induced levels of sICAM-1, sVCAM-1, and cathepsin D at 60 min post-METH infusion. CONCLUSIONS: Our findings demonstrate that IBUD attenuated acute pro-inflammatory effects of METH administration, which may have implications for treatment of METH use disorder.
RCT Entities:
BACKGROUND: Preclinical studies suggest that the non-selective phosphodiesterase inhibitor, Ibudilast (IBUD) may contribute to the treatment of methamphetamine (METH) use disorder through the attenuation of METH-induced inflammatory markers such as adhesion molecules, sICAM-1 and sVCAM-1, and cytokines, IL-6 and TNF-α. OBJECTIVE: The present study aimed to test whether treatment with IBUD can attenuate peripheral markers of inflammation during a METH challenge in an inpatient clinical trial of 11 patients. METHODS: This trial followed a randomized, within-subjects crossover design where participants received a METH challenge, during which five participants were treated with placebo then with IBUD, while the remaining six participants were treated with IBUD prior to placebo. Mixed effects regression modeled changes in peripheral markers of inflammation-sICAM-1, sVCAM-1, TNF-α, IL-6, MIF, and cathepsin D-by treatment condition, with measurements at baseline, 60 min post-METH infusion, and 360 min post-METH infusion. RESULTS: While on placebo, sICAM-1, sVCAM-1, and cathepsin D significantly increased by 60 min post-METH infusion, while IL-6 significantly increased 360 min post-METH infusion. Treatment with IBUD significantly reduced METH-induced levels of sICAM-1, sVCAM-1, and cathepsin D at 60 min post-METH infusion. CONCLUSIONS: Our findings demonstrate that IBUD attenuated acute pro-inflammatory effects of METH administration, which may have implications for treatment of METH use disorder.
Authors: Lucien C D Gibson; Stuart F Hastings; Ian McPhee; Robert A Clayton; Claire E Darroch; Alison Mackenzie; Fiona L Mackenzie; Michiaki Nagasawa; Patricia A Stevens; Simon J Mackenzie Journal: Eur J Pharmacol Date: 2006-03-13 Impact factor: 4.432
Authors: Matthew J Worley; Aimee-Noelle Swanson; Keith G Heinzerling; Daniel J O Roche; Steve Shoptaw Journal: Drug Alcohol Depend Date: 2016-03-03 Impact factor: 4.492
Authors: Joan E Zweben; Judith B Cohen; Darrell Christian; Gantt P Galloway; Michelle Salinardi; David Parent; Martin Iguchi Journal: Am J Addict Date: 2004 Mar-Apr
Authors: Marilyn Huckans; Bret E Fuller; Alison L N Chalker; Madeleine Adams; Jennifer M Loftis Journal: Front Psychiatry Date: 2015-12-18 Impact factor: 4.157
Authors: Michael J Li; Emily I Richter; Chukwuemeka N Okafor; Mariah M Kalmin; Shareefa Dalvie; Sae Takada; Pamina M Gorbach; Steven J Shoptaw; Steven W Cole Journal: Ann Behav Med Date: 2022-08-30
Authors: Edythe D London; Kyoji Okita; Kaitlin R Kinney; Andrew C Dean; Megan N McClintick; Elizabeth J Rizor; Maritza C Johnson; Tarannom Mahmoudie; Arthur L Brody; Erika L Nurmi; Lauren C Seaman; Judah Farahi; Nathaniel Ginder; Mark A Mandelkern Journal: Drug Alcohol Depend Date: 2020-06-11 Impact factor: 4.852
Authors: C Leonardo Jimenez Chavez; Camron D Bryant; Melissa A Munn-Chernoff; Karen K Szumlinski Journal: Int J Mol Sci Date: 2021-05-21 Impact factor: 5.923